Hematology

City of Hope Comprehensive Cancer Center earns highest ranking from National Cancer Institute

Retrieved on: 
Thursday, February 16, 2023
City, Health, NCI, Physician, City of Hope, CAR, Irell & Manella Graduate School of Biological Sciences, National Cancer Institute, Pharmacist, City of Hope National Medical Center, Publication, Drug development, Radiation, Patient, Research, Neoplasm, Hematology, Cancer, LOS, Nursing, Pharmaceutical industry, Dietary supplement, Hope

$23 million also awarded for research, training and community outreach

Key Points: 
  • $23 million also awarded for research, training and community outreach
    LOS ANGELES, Feb. 16, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that its comprehensive cancer center has received the highest rating possible for a U.S. cancer center — "exceptional" — by the National Cancer Institute (NCI), the federal government's principal agency for cancer research and training.
  • The ranking puts the center in the top echelon of the nation's 53 NCI-designated comprehensive cancer centers.
  • City of Hope has held the prestigious NCI designation since it became an NCI-designated cancer center in 1981.
  • City of Hope's Los Angeles campus, located in Duarte, is the location of its NCI-designated comprehensive cancer center, which is the research and innovation hub for its national cancer system.

FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma

Retrieved on: 
Tuesday, February 14, 2023
AOCNP, MCL, NHL, Estate (law), Spleen, Drug development, National Institute of Nursing Research, FCS, Abstract, B-cell lymphoma, Reversibility, Diagnosis, Safety, Bone marrow, Hematology, Patient, Clinician Administered PTSD Scale, Liver, Lymph, Mantle cell lymphoma, Relapse, FACP, Clinical research, FDA, Growth, Prognosis, MSN, Progression-free survival, Society, BTK, Cancer, MD, Pharmaceutical industry, Vaccine

"It is rewarding to see the impact of our work in developing this drug from the initial trial."

Key Points: 
  • "It is rewarding to see the impact of our work in developing this drug from the initial trial."
  • - Manish Patel, MD
    Pirtobrutinib (Jaypirca™) is the first next-generation BTK inhibitor specifically approved by the FDA for adult patients with mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL), which affects about one in 200,000 people worldwide each year.
  • Following an expedited review of the outcomes observed in the BRUIN 18001 study, the FDA granted Pirtobrutinib an accelerated approval.
  • To read the full study abstract: https://ash.confex.com/ash/2022/webprogram/Paper157058.html
    Access the current list of FCS clinical trials: https://flcancer.com/clinical-trials/

Dr. Lisa D. Ahrendt is recognized by Continental Who's Who

Retrieved on: 
Monday, February 13, 2023
Trinity Methodist Church, American Society of Clinical Oncology, American Medical Association, Acute leukemia, Breast, Drexel University, Continental, Former Trinity Methodist Church, Dunedin, Tufts Medical Center, Patient, Internal medicine, Research, Oncology, Clinical Lung Cancer, Disease, Camping, Nursing, Society, Hematology, Chronic lymphocytic leukemia, Skiing, BS, Cancer, Washington University in St. Louis, MD, Biology

DENVER, Feb. 13, 2023 /PRNewswire/ -- Dr. Lisa D. Ahrendt is being recognized by Continental Who's Who as a Distinguished Healthcare Provider for her contributions to the medical field.

Key Points: 
  • DENVER, Feb. 13, 2023 /PRNewswire/ -- Dr. Lisa D. Ahrendt is being recognized by Continental Who's Who as a Distinguished Healthcare Provider for her contributions to the medical field.
  • Dr. Ahrendt attended Washington University in St.Louis and earned a BS in Biology.
  • She then received an MD from the Hahnemann School of Medicine in Philadelphia, Pennsylvania (Drexel University).
  • Dr. Ahrendt believes that the key to the successful treatment of cancer has a team-based approach.

More IVD Testing to be Performed POC at Physician Office Lab Venues: Kalorama Report

Retrieved on: 
Monday, February 6, 2023
Physician, COVID-19 testing, Laboratory, Hospital, Chlamydia, Tuberculosis, Pneumonia, Patient, Hepatitis, HIV, Nursing care plan, POC, Glycated hemoglobin, IVD, Bed, Test market, Hematology, COVID-19, Glucose, Immunoassay, Cancer, Microbiology, Malaria, Nursing, Pharmaceutical industry, Medical device

ARLINGTON, Va., Feb. 6, 2023 /PRNewswire-PRWeb/ -- The in vitro diagnostics (IVD) market follows patients where technologies allow. There's no greater evidence of the need for IVD product makers to find a market in physician office labs than the declining hospital bed count. With declining hospital beds in developed countries and slow growth in hospital bed volume even in developing nations, it makes sense that more testing will be shifted in venue to the point of care.

Key Points: 
  • Physician Office In Vitro Diagnostic (IVD) Test Markets , a January 2023 report published by leading medical market research firm Kalorama Information, projects IVD product sales of over $8.3 billion in 2022.
  • The report, "Physician Office In Vitro Diagnostic (IVD) Test Markets," reveals that 770 million world physician office visits will occur in 2023, providing ample opportunity for testing.
  • the increasing availability of point-of-care (POC) IVD testing in retail establishments and hospital outpatient departments will hold down the overall global volume of traditional physicians' office testing.
  • For more information or to purchase the market research report "Physician Office In Vitro Diagnostic (IVD) Test Markets," visit: https://kaloramainformation.com/product/physician-office-in-vitro-diagno... .

This Week in Health News: 10 Stories You Need to See

Retrieved on: 
Friday, February 3, 2023
Ageing, PR Newswire, Center for Drug Evaluation and Research, Obesity, Division, Anemia, Endoscopy, Super Bowl, Risk, Disease, Dialysis, FDA, MD, Chronic kidney disease, FACS, CVD, Research, ASMBS, COVID-19, Hematology, Cardiovascular disease, Cancer, Mental health, News, Pharmaceutical industry

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • A roundup of the week's most newsworthy health industry press releases from PR Newswire, including a survey of Americans' top health concerns.
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
  • Survey respondents (22%) said heart disease is their number one health concern, topping mental health, cancer, COVID-19, and a list of other diseases and conditions.
  • This includes medication, surgery, endoscopy, lifestyle changes and behavioral health interventions," said ASMBS President Teresa LaMasters, MD, FACS, FASMBS, DABOM.

Contract Research Organization (CRO) Services Market worth $127.3 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 2, 2023
Ophthalmology, Vaccine, Infection, Neurology, CVS, System, Health, Dermatology, Contract research organization, Data management, Hematology, Prevalence, Clalit Health Services, Psychiatry, Fine chemical, Pharmaceutical industry, IQVIA

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2022.

Key Points: 
  • The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2022.
  • Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services.
  • The clinical research services segment accounted for the largest share of this market in 2022.
  • Contract Research Organization (CRO) Services Market Dynamics:
    In November 2022, IQVIA (US) collaborated with Clalit Health Services (Israel) to combine their clinical trial delivery, real-world research, data, and genomics capabilities.

Contract Research Organization (CRO) Services Market worth $127.3 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 2, 2023
Ophthalmology, Vaccine, Infection, Neurology, CVS, System, Health, Dermatology, Contract research organization, Data management, Hematology, Prevalence, Clalit Health Services, Psychiatry, Fine chemical, Pharmaceutical industry, IQVIA

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2022.

Key Points: 
  • The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2022.
  • Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services.
  • The clinical research services segment accounted for the largest share of this market in 2022.
  • Contract Research Organization (CRO) Services Market Dynamics:
    In November 2022, IQVIA (US) collaborated with Clalit Health Services (Israel) to combine their clinical trial delivery, real-world research, data, and genomics capabilities.

FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis

Retrieved on: 
Wednesday, February 1, 2023
China Biologic Products, Dizziness, Vaccine, Human services, Food, Blood, Erythropoietin, Office of Inspector General, U.S. Department of Health and Human Services, Heated tobacco product, Hospital, Animal, Abdominal pain, Patient, Safety, Center for Drug Evaluation and Research, Gastrointestinal bleeding, Division, Oxygen, Skin, Anemia, GSK plc, Risk, Death, Stroke, Dialysis, FDA, Allergy, Chronic kidney disease, Research, Dietary supplement, Public, Conditional sentence, Multimedia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hematology, Heart failure, Blood pressure, Cosmetics, Tablet, Pharmaceutical industry

More than a half million adults in the U.S. have chronic kidney disease requiring dialysis (a treatment that filters the blood and removes excess fluid from the blood).

Key Points: 
  • More than a half million adults in the U.S. have chronic kidney disease requiring dialysis (a treatment that filters the blood and removes excess fluid from the blood).
  • In a person with chronic kidney disease on dialysis, the kidneys cannot produce enough erythropoietin, leading to reduced numbers of red blood cells.
  • In this study, adults received either oral Jesduvroq or injected recombinant human erythropoietin (a standard of care treatment for patients with anemia due to chronic kidney disease).
  • Jesduvroq is not approved for patients with anemia due to chronic kidney disease who are not on dialysis because its safety has not been established in that population.

APSHO Announces Launch of New Cancer Therapy Prescribing Course

Retrieved on: 
Wednesday, February 1, 2023
AP, Therapy, Pharmacist, Cancer, Practitioner, Clinical trial, FNP, Ape Academy 2, MSN, Hematology, APS, Nursing

LAWRENCEVILLE, N.J., Feb. 1, 2023 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) is proud to announce the launch of the APSHO Cancer Therapy Prescribing Course (CTPC). This comprehensive, online course consists of 19 self-paced, interactive educational modules designed to prepare the advanced practitioner (AP) to safely prescribe and manage cancer therapeutics. The Cancer Therapy Prescribing Course provides peer-reviewed, advanced education in the treatment and management of the hematology/oncology patient through the course of cancer therapy and includes safe prescribing recommendations, treatment access devices, the prevention and management of infusion reactions, patient education, and clinical trial prescribing.

Key Points: 
  • LAWRENCEVILLE, N.J., Feb. 1, 2023 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) is proud to announce the launch of the APSHO Cancer Therapy Prescribing Course (CTPC) .
  • The Cancer Therapy Prescribing Course provides peer-reviewed, advanced education in the treatment and management of the hematology/oncology patient through the course of cancer therapy and includes safe prescribing recommendations, treatment access devices, the prevention and management of infusion reactions, patient education, and clinical trial prescribing.
  • Briana Hoffner, MSN, AOCNP®, FAPO, BroadcastMed's Chief Medical Officer, noted, "APSHO's Cancer Therapy Prescribing Course was developed by an expert, dedicated, multidisciplinary group of APs, including pharmacists, physician assistants, and nurse practitioners.
  • The course encompasses all of the required educational domains for the safe prescribing of cancer therapy."

Florida Cancer Specialists & Research Institute Appoints Hitesh Patel, MD to Executive Board

Retrieved on: 
Wednesday, February 1, 2023
Oncology, FCS, Kingsbrook Jewish Medical Center, Internal medicine, Patient, Kasturba Medical College, University, H. Lee Moffitt Cancer Center & Research Institute, Partnership, Environment, University of South Florida College of Medicine, Kingsbrook, American Society of Pediatric Hematology/Oncology, MD, Nursing, Hematology

Fort Myers, Fla., Feb. 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

Key Points: 
  • Fort Myers, Fla., Feb. 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.
  • Triple Board-certified in Hematology, Medical Oncology and Internal Medicine, Dr. Patel provides care to patients at two FCS clinic locations in Clearwater, Florida – Axelrod and Clearwater North McMullen Booth.
  • We appreciate his willingness to serving in this capacity to advance the delivery of world-class cancer care in a rapidly changing and challenging environment."
  • The FCS Executive Board provides strategic direction for the statewide practice, deriving clear objectives and goals to ensure its overall success.